

Becton Dickinson and Co (BDX)

	Market Data
Last Close	244.25
Price 52 Week High	286.72
Price 52 Week Low	197.75
Market Cap (M)	\$72,128.29
Enterprise Value (M)	\$87,216.29

	Wall St. Recos
Strong Buy	5
Buy	6
Hold	6
Sell	0
Sell	0

	Price Targets
Price Target - Mean	275.57
Price Target - Number of Included Estimates	14
Price Target - High	300
Price Target - Low	255
Price Target - Standard Deviation	13.78
Long Term Growth - Mean	9.5
Lido Estimate	272
Upside	11.36

Multiples	LTM	NTM
EV/SALES	5.1	5.1
EV/EBITDA	18.2	18.2
EV/EBIT	33.07	33.07
P/E	90.88	90.88
P/B	3.03	3.03
ROA (%)	1.65	1.65
ROE (%)	3.9	3.9
PEG	9.57	9.57

Key Points

Should benefit for economic recovery in the next two years as hospitals start to deploy cash towards Capex. Growth in BDX's hospital capital equipment has suffered because hospitals have been hesitant to deploy cash given the drop in elective procedures.

One of the largest syringe makers and will see a direct benefit from vaccine delivery.

Alaris (Infusion pump) was recalled and is going through a review process. Stock down 10% on that news earlier this year. Company should file for review in 2Q 2021.

Despite the setback of Alaris, BDX has been able to reaffirm their earnings guidance

Main risk would be a setback to the Alaris timeline.